ASCO 2012: advances in high-risk prostate cancer; neoadjuvant abiraterone

Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Mary-Ellen Taplin, Dana-Farber Cancer Institute, USA Dr Chris Parker, Royal Marsden Cancer Centre, London, UK, talks to Dr Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, USA, about her presentation on the effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer.? ? Dr Taplin comments on the exciting results of this phase II study that shows firstly that biopsies performed confirmed that abiraterone was lowering the androgen hormone levels in the tissue (not only in the blood as previously shown). Also that one third of patents had no or very little tumour left in their prostate after abiraterone therapy. Dr Taplin also comments on follow-up studies now being conducted. ? This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). ASCO 2012 ? Cytotoxics ? Hormones/endocrine ? Prostate & urology

13 Jun 2012 Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies Dr George Demetri - Dana-Farber Cancer Institute, Boston, USA ecancer talks to Dr George Demetri, Dana-Farber Cancer Institute, Boston, USA, at the 2012 ASCO meeting, Chicago. ? Results of an international Phase III trial demonstrate that the new targeted oral drug, regorafenib, can improve outcomes for patients with gastrointestinal stromal tumours (GIST) that progress due to resistance to other available treatment options, including imatinib and sunitinib. ? The researchers found that progression-free survival was four times longer among patients receiving regorafenib than among those receiving placebo; all patients also received best supportive care to alleviate the symptoms of their disease. 12 Jun 2012 ASCO 2012: Advances in myeloma Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof Gareth Morgan - Royal Marsden Hospital, UK Dr Philippe Moreau, Centre Hospitalier Universitaire de Nantes, France, gives Prof Gareth Morgan, Royal Marsden Hospital, London, UK, his thoughts on the myeloma session held on the 3rd day of ASCO 2012. ? He first outlines the promising results from the carfilzomib combination studies, eg, with MP and with len+dex, and comments on results with the investigational oral proteasome inhibitor, MLN9708, as well as recent data with pomalidomide and panobinostat. ? Dr Moreau goes on to outline initial results presented at ASCO of the bendamustine, bortezomib, dexamethasone (BVD) study in elderly patients with relapsed/refractory multiple myeloma which showed a 67% response rate in this patient group after four cycles. ? This programme was made possible with an educational grant provided by Mundipharma.? 12 Jun 2012 ASCO 2012: advances in high-risk prostate cancer; neoadjuvant abiraterone Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Mary-Ellen Taplin, Dana-Farber Cancer Institute, USA Dr Chris Parker, Royal Marsden Cancer Centre, London, UK, talks to Dr Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, USA, about her presentation on the effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer.? ? Dr Taplin comments on the exciting results of this phase II study that shows firstly that biopsies performed confirmed that abiraterone was lowering the androgen hormone levels in the tissue (not only in the blood as previously shown). Also that one third of patents had no or very little tumour left in their prostate after abiraterone therapy. Dr Taplin also comments on follow-up studies now being conducted. ? This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). 12 Jun 2012 ASCO 2012: Metastatic castration-resistant prostate cancer; abiraterone acetate COU-AA-302 study Dr Chris Parker - Royal Marsden Cancer Centre, UK; Dr Karim Fizazi from Institut Gustave Roussy, France Dr Chris Parker, Royal Marsden Cancer Centre, London, UK, talks to Dr Karim Fizazi from Institut Gustave Roussy, Paris, France, about the interim results of the COU-AA-302 study.? This was a large, randomized, phase III study of abiraterone acetate plus prednisone vs. placebo plus prednisone in chemotherapy-naive, asymptomatic/mildly symptomatic patients with metastatic castration-resistant prostate cancer (mCRPC). ? Dr Fizazi discusses the promising results of this interim analysis showing that PFS almost doubled with abiraterone plus prednisone vs. placebo plus prednisone, and the strong trend for increased OS. He also comments on the implications of these results for the use of abiraterone in these less-advanced mCRCP patients. Dr Fizazi explains the Independent Data Monitoring Committee decision to unblind the study and cross patients from placebo to abiraterone at this interim analysis.? ? Dr Fizazi additionally comments on his study assessing the value of prognostic factors/markers on predicting OS in patients with bone metastases with CRPC. ? This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). 12 Jun 2012 ASCO 2012: Advances in pre-operative care in high-risk mCRCP Dr Chris Parker - Royal Marsden Cancer Centre, UK; Prof Eleni Efstathiou - MD Anderson Cancer Centre, USA Dr Chris Parker, Royal Marsden Cancer Centre, London, UK, talks to Prof Eleni Efstathiou from the MD Anderson Cancer Centre, Texas, USA, who discusses her presentation at ASCO 2012 of preliminary results (n=40) of a randomized pre-operative study. The study focuses on cytoreduction and androgen signaling modulation by abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer. ? Prof Efstathiou outlines the exciting results in the abiraterone group, and notes the promise this shows for high-risk mCRCP patients. She also comments on the almost 100% use of robotic radical prostatectomy in study patients. ? Whilst these results are early, Prof Efstathiou comments on the potential implication of these findings over the next few years, with the great promise of using newer drugs pre-operatively in high-risk mCRCP. ? Prof Efstathiou also comments on the use of bone marrow samples to predict response and/or outcome to abiraterone in high-risk patients. ? This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).? 12 Jun 2012 ASCO 2012: Advances in lymphoma; bendamustine combination in indolent lymphoma Prof John Gribben - Barts & The London Trust Cancer Centre, UK; Prof Mathias Rummel - University Hospital Giessen, Germany Prof John Gribben from Barts & The London Trust Cancer Centre, UK talks to Prof Mathias Rummel, University Hospital Giessen, Germany, on his plenary session presentation at ASCO 2012. This focuses on the results of the STiL NHL 1 study comparing bendamustine/rituximab (B-R) vs. CHOP-R as a first-line treatment in patients with indolent and mantle cell lymphomas (MCL). ? Prof Mathias outlines the improved toxicity of the B-R regimen (eg, lack of hair loss), including no difference between the two regimens in late-toxicity, including in MDS. ? He also outlines the superiority in efficacy of B-R compared to CHOP-R in all lymphoma etiologies included in the study. Relapses were higher with CHOP-R vs. B-R. Although no differences in overall survival were noted between the regimens, the study was not powered for this.? B-R should now be the first-line treatment in lymphoma, and several new combination studies with B-R are now on-going. ? This programme was made possible with an educational grant provided by Mundipharma.? More information here 12 Jun 2012 ASCO 2012: Advances in metastatic castration-resistant prostate cancer; first-line cabazitaxel Dr Chris Parker - Royal Marsden Cancer Centre, London, UK; Prof St?phan Oudard - H?pital Europ?en Georges Pompidou, France Dr Chris Parker, Royal Marsden Cancer Centre, London, UK, talks to Prof St?phan Oudard, H?pital Europ?en Georges Pompidou, France, about his abstract presented at ASCO 2012 concerning the first-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). This was a three-arm study in comparison with docetaxel that followed on from the TROPIC trial of cabazitaxel in the second-line setting. ? Prof Oudard comments that cabazitaxel appears to be more active than docetaxel and with an improved safety profile, and outlines the study results. He emphasises the need to use gCSF when using cabazitaxel in order to prevent neutropenia. ? Prof Oudard explains the rationale behind the two doses of cabazitaxel used in the study (25mg/m? IV Q3W and 20mg/m? IV Q3W). He stresses the future need to personalise choice of treatments to individual patients, and suggests the future role of chemotherapy vs. newer non-chemotherapy based treatments. ? This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). 12 Jun 2012 ASCO 2012: Advances in metastatic castration-resistant prostate cancer with abiraterone Dr Karim Fizazi - Institut Gustave Roussy, France; Dr Oscar Goodman - Nevada Cancer Institute, USA Dr Karim Fizazi from Institut Gustave Roussy, Paris, France, talks to Dr Oscar Goodman from the UC San Diego Nevada Cancer Institute in Las Vegas, USA, on new data presented at ASCO 2012 on abiraterone in metastatic castration-resistant prostate cancer (mCRPC). ? Dr Goodman reminds the viewers of the COU-AA-301 study comparing abiraterone vs. prednisone post-doxetaxel in mCRPC.? He then outlines the new post-hoc analysis of this study looking at the amount of doxetaxel received prior to abiraterone therapy, the interval between completion of doxetaxel and initiation of abiraterone, and the reason for discontinuation of doxetaxel.? ? Dr Goodman comments on the new finding from this post-hoc analysis that highlights the importance of drug administration timing in disease management, and notes the hope that this study offers to patients to move this cancer from deadly to a chronic disease. ? This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company). 04 Jun 2012 President's overview of ASCO 2012 Dr Michael Link - Stanford School of Medicine, California, USA Outgoing ASCO President Dr Michael Link talks to?ecancer about cancer drug shortages and new drug developments at the ASCO 2012 Annual Meeting in Chicago, June 2012. ? Dr Link discusses his presentation on cancer drug shortages and efforts to combat them, in addition to field radiotherapy with Stanford V Regimen. Results from a?number of trials with favourable outcomes were presented at the ASCO 2012 Annual Meeting; trastuzumab?emtansine (TDM1) a new option for HER2 positive metastatic breast cancer; regorafenib, a life giving option for patients with imatinib resistant GIST; and bendamustin used in combination with rituximab, in place of CHOP, for indolent lymphoma. ? Audio only 04 Jun 2012 Drug shortage impact on cancer care and efforts to resolve the issue Dr Sandra Kweder - US Food and Drug Administration At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Sandra Kweder presents on the impact of recent drug shortages and ways to prevent shortages in the future. 04 Jun 2012 Patient perspective on drug shortages Dr Michael Link - Stanford University School of Medicine, California, USA At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, ASCO President Dr Michael Link discusses his experience with drug shortages and how his patients felt about the situations. 04 Jun 2012 Recommendations for averting drug shortages Dr Richard Schilsky - University of Chicago, USA At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr Richard Schilsky presents ASCO's recommendations for averting drug shortages

timothy leary jonathan frid pujols watchmen hitch justin beiber lamar odom